Wilke T, et al. – This study was undertaken to examine discontinuation–, re–initiation– or continuation–rates of a 2nd biological disease modifying anti-rheumatic drugs (bDMARDs) therapy as well as switching–rates to a third biological DMARD (3rd bDMARD) therapy in rheumatoid arthritis (RA) patients. A continuation of 2nd bDMARD treatment after 12 months in only 56.8% of cases was reported; 60% if re–start was included. In addition, a higher probability of continuing 2nd bDMARD therapy was observed in non–anti–TNF patients.